理邦仪器2025年净利润同比预增75%至105%

Core Viewpoint - The company, Edan Instruments, forecasts a net profit attributable to shareholders of 284 million to 332 million yuan for 2025, representing a year-on-year growth of 75% to 105% [1] Group 1: Financial Performance - The company expects steady growth in overall revenue for 2025, particularly in international markets, which are projected to maintain double-digit growth [1] - Non-recurring gains and losses are anticipated to impact net profit by approximately 14 million yuan, mainly from government subsidies, which is a decrease of around 4 million yuan compared to the previous year [1] Group 2: Business Strategy - The company continues to focus on its development strategy of "innovation, platform-based, and internationalization," enhancing its global business layout and service capabilities in overseas markets [1] - Edan Instruments is accelerating new product development and optimizing its marketing system while advancing its overseas manufacturing strategy [2] - The company has been collaborating with the Gates Foundation, with progress on handheld ultrasound devices reaching clinical validation and confirmation stages [2] Group 3: Operational Developments - A new facility in the U.S. covering 1,940 square meters has been added to enhance the company's business layout in North America and improve supply chain resilience [2] - The new facility has received comprehensive certifications, including MDSAP certification and the California FDB medical device production license [2] - The company plans to flexibly arrange domestic and overseas production capacity based on order demand after the new U.S. facility is operational, which is expected to enhance profitability in the long term [3]